Analyst firms · Barclays · ABT

Barclays ABT price target and rating history

Abbott Laboratories (ABT) · Health Care

Barclays rates Abbott Laboratories (ABT) Overweight with a $120 price target, as of its latest action on Oct 7, 2026. It has published 3 rating actions on ABT since October 2022, including 0 upgrades and 0 downgrades. Across 5 firms with a ABT price target in the last 12 months, the median target is $121. Barclays's $120 is 1% below that.

Current rating

Overweight

Price target

$120

Median target, all firms

$121

Actions on ABT

3

Barclays price target on ABT

Every Barclays rating on ABT

• Oct 7, 2026
  InitiateBarclays starts coverage at Overweight, price target $120
• Apr 20, 2023
  ReiterateBarclays raises its price target to $127 from $125, keeps Overweight
• Oct 18, 2022
  InitiateBarclays starts coverage at Overweight, price target $118

How other firms rate ABT

Each firm's latest rating and stated target in the last 12 months.

Questions about Barclays and ABT

What is Barclays's price target for ABT?

Barclays's latest stated price target for Abbott Laboratories (ABT) is $120, from its action on Oct 7, 2026.

What is Barclays's rating on ABT?

Barclays rates ABT Overweight, a bullish rating, as of Oct 7, 2026.

When did Barclays last change its view on ABT?

On Oct 7, 2026, Barclays starts coverage at Overweight, price target $120.

How does Barclays's ABT target compare with other analysts?

Across 5 firms with a ABT price target in the last 12 months, the median target is $121. Barclays's $120 is 1% below that.

More ABT rating histories

• Wolfe Research4
• Leerink Partners3
• Morgan Stanley5
• Raymond James5
• UBS3

All Barclays ratingsABT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.